&w=3840&q=100)
Whiteland Corp launches Marriott's first branded residence in Gurugram
Delhi-NCR-based Whiteland Corporation on Friday announced the launch of Marriott International's first Westin-branded residences in India, with the development expected to have a projected topline of ₹15,000 crore.
This comes after the company signed an exclusive agreement with Marriott International in June 2024 to collaborate on the project.
Navdeep Sardana, founder of Whiteland Corporation, told Business Standard that the total investment in The Westin Residences, Gurugram, would be ₹5,600 crore, with the project expected to be completed by 2031.
Expected to be the largest standalone branded residences project announced in India, the 20-acre development will include 1,700 three and four BHK residences, ranging from 2,673 to 4,328 square feet in size.
Sardana stated that currently 1,464 units are being launched in the first phase. 'Phase 1 of the launched project will include a select offering of residences, whereas Phase 2, which will include towers, is planned for a future launch,' he added.
According to people in the know, the price range for The Westin Residences, Gurugram, is between ₹6 crore and ₹12 crore, depending on size, configuration, and location within the development.
Sardana added that The Westin Residences, Gurugram, will be a 100 per cent Whiteland Corporation development, with complete investment and execution managed by Whiteland, while Marriott International has extended its brand under a licence agreement.
'As part of our agreement with Marriott International, Whiteland holds exclusive branding rights for Westin Residences in the territories of Gurugram, Dwarka Expressway, and select parts of Delhi until 2032,' he said.
The company is not planning to launch any other Westin-branded residential projects within this exclusive territory during that period.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
36 minutes ago
- Hindustan Times
Australian techie says TCS job changed his life: ‘Whatever I have today, I owe to TCS'
A former employee of Tata Consultancy Services has thanked the IT services company for changing his life. Vinay Sriram has more than a decade of work experience and currently works as a Test Lead for the Reserve Bank of Australia - but the Sydney-based professional says he owes all his professional success to his first job at TCS. 'Whatever little I have today in life I owe it to TCS,' Sriram wrote in a post shared on the social media platform X. The India-born Australian techie was responding to a post about how TCS has alleviated millions out of poverty. has reached out to TCS for a statement. This story will be updated on receiving a response. Vinay Sriram started his career with TCS as a Software Test Analyst. In his thread, he remembered how getting his first job at TCS made his father proud. 'I vividly remember my dad's reaction when I said I got placed in TCS. (Though we were not a struggling family). It was one of those few moments where he hugged me and teared up at around 10 in the night when I returned home after my campus interview,' he recalled. Though his father held a stable government job and the family was financially secure, Sriram acknowledged that for countless other students, a job at TCS was nothing short of life-changing. 'If it meant that much to my dad, a central Govt servant with a decent salary, imagine what it would mean to 1st Gen graduates and their parents, students coming from towns and villages who had to face bigger battles like oppression to even get to a half decent college,' he said. Sriram also thanked TCS for paving the way for him to reach Australia and for indirectly helping him meet his wife. 'The opportunity to travel to Sydney, a place I dearly call my home today, is something TCS gave me,' he said on X. The techie revealed that after getting a job at TCS through campus placement, he was waiting for his date of joining when he helped a junior prepare for the TCS interview. He eventually ended up marrying her. 'as a side note, a year later while waiting for my Date of Joining, by helping a junior with her TCS interview prep (Though she didn't make it & ended up joining Renault) I eventually found the love of my life and ended up marrying her and have two beautiful kids with her,' he said. Sriram responded to the hate that TCS gets on social media by saying that 'One man's trash is another man's Treasure.' 'TCS is my treasure that gifted me the life I am living today,' he wrote.
&w=3840&q=100)
Business Standard
44 minutes ago
- Business Standard
Biocon share price pops 2% on CDSCO nod for diabetes drug; key details here
Biocon share price: Bengaluru-based biopharmaceutical company Biocon shares were in demand in a weak market on Tuesday, June 3, 2025, with the stock rising up to 1.85 per cent to hit an intraday high of 340.25 per share. However, at 11:00 AM, Biocon share price was trading 0.49 per cent higher at 335.70 per share. What is the reason behind the uptick in Biocon share price? Biocon's share price saw an uptick following key regulatory approvals in India for its Liraglutide drug. The company received approval from the Central Drugs Standard Control Organisation (CDSCO) for its Liraglutide drug substance, while its wholly owned subsidiary, Biocon Pharma, secured approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge). Liraglutide is a synthetic analog of the GLP-1 peptide and is administered as a once-daily injection. It is a generic version of Victoza and is indicated for the treatment of Type 2 Diabetes Mellitus in adults, adolescents, and children aged 10 years and older, as an adjunct to diet and exercise. The original formulation was approved in the EU in 2009 and in the US in 2010. The approvals were granted under the CDSCO's recently introduced 101 route, which recognises approvals from established global regulatory authorities, streamlining the approval process in India. Siddharth Mittal, chief executive officer and managing director, Biocon, said: 'The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest numbers of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocon's mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India'' 'With GLP-1 therapies projected to be a substantive future growth driver for Biocon, the Company remains committed to reinforcing its position as a key player in this area,' Biocon said, in a statement. Biocon Q4 results Biocon reported a strong financial performance for the fourth quarter of FY25, with consolidated net profit surging 153 per cent year-on-year (Y-o-Y) to ₹344 crore, up from ₹136 crore in the same quarter last year. Profit before tax (PBT) rose 53 per cent Y-o-Y to ₹487 crore. The company's Board also approved plans to raise up to ₹4,500 crore through various funding options, including qualified institutional placement (QIP), rights issue, or other permissible methods. The robust growth was driven by solid performance across its generics, biologics, and research services segments. Total consolidated revenue for the quarter stood at ₹4,454 crore, compared to ₹3,966 crore in Q4 FY24. Ebitda rose 16 per cent to ₹1,115 crore, with the margin maintained at 25 per cent. READ MORE About Biocon Biocon is a global biopharmaceutical company focused on developing and supplying affordable therapies for chronic diseases such as diabetes, cancer, and autoimmune disorders. The company manufactures and markets novel biologics, biosimilars, complex small molecule APIs, and generic formulations across India, the US, Europe, and other key markets. It is also advancing a pipeline of novel immunotherapy assets.
Hindustan Times
an hour ago
- Hindustan Times
Meenakshi Group to raise up to ₹700 crore for a real estate-focused alternate investment fund
Hyderabad-based real estate firm Meenakshi Group has announced that it will raise up to ₹700 crore for a realty-focused alternative investment fund (AIF), the Meenakshi Real Assets Fund. The company has committed 20% of the corpus size as sponsor capital for the fund, the company said. The fund, with a total corpus of ₹700 crore (including a ₹350 crore greenshoe option), will follow a hybrid investment strategy by deploying capital across both debt and equity instruments, the company said. With a six-year investment horizon, the Meenakshi Real Assets Fund will target 6 to 8 high-conviction deals, focusing on self-liquidating real estate assets that offer a combination of steady cash flows and capital appreciation. The fund is geared toward working with Tier I developers operating in high-growth micro-markets across key urban centres, with deal sizes of up to ₹70 crore per transaction, the company said. Also Read: ASK Property Fund, ISIR-backed real estate AIF raises ₹500 crore for Investment in luxury housing projects 'Securing the AIF license allows us to bring institutional-grade, well-structured investment products to the market. We're already seeing strong early interest, and we have three deals currently under due diligence. We've also received soft commitments from the Meenakshi Group, its wider network, and early investors," Mahesh Katragadda, CEO of Meenakshi Alternates, said. 'Our goal is to build long-term trust and deliver consistent returns by leveraging our strong track record in real estate. We are focused on creating value through disciplined capital deployment and high-quality investment opportunities," he said.
